VENTYX BIOSCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.285 USD | +2.76% |
|
-3.83% | +72.87% |
| 05-09 | Transcript : Ventyx Biosciences, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| 05-09 | Ventyx Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 998.9 | 1,857 | 145.8 | 294 | - | - |
| Enterprise Value (EV) 1 | 998.9 | 1,539 | -155 | 69.66 | -101.7 | 166.2 |
| P/E ratio | -2.99 x | -15.8 x | -0.75 x | -1.72 x | -1.59 x | -2.44 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 4.41 x |
| EV / Revenue | - | - | - | - | - | 2.49 x |
| EV / EBITDA | - | -13.6 x | 0.75 x | -0.43 x | 0.65 x | -0.89 x |
| EV / FCF | -25.7 x | -15.5 x | 0.93 x | -0.56 x | 0.61 x | -0.83 x |
| FCF Yield | -3.9% | -6.43% | 108% | -178% | 164% | -120% |
| Price to Book | - | 5.28 x | 0.59 x | 0.81 x | 0.62 x | - |
| Nbr of stocks (in thousands) | 50,297 | 56,637 | 59,027 | 70,494 | - | - |
| Reference price 2 | 19.86 | 32.79 | 2.470 | 4.170 | 4.170 | 4.170 |
| Announcement Date | 22-03-23 | 23-03-23 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 66.7 |
| EBITDA 1 | - | - | -113 | -207.8 | -162.5 | -157.3 | -187.2 |
| EBIT 1 | - | -67.15 | -113.1 | -208 | -164.5 | -179.7 | -160.1 |
| Operating Margin | - | - | - | - | - | - | -240.05% |
| Earnings before Tax (EBT) 1 | - | -83.75 | -108.4 | -193 | -161.9 | -193.3 | -154.3 |
| Net income 1 | -28.17 | -85.3 | -108.4 | -193 | -159.5 | -182.9 | -150.4 |
| Net margin | - | - | - | - | - | - | -225.5% |
| EPS 2 | -14.16 | -6.650 | -2.070 | -3.300 | -2.428 | -2.621 | -1.710 |
| Free Cash Flow 1 | - | -38.91 | -99.05 | -167 | -124 | -167 | -199.5 |
| FCF margin | - | - | - | - | - | - | -299.11% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 21-08-20 | 22-03-23 | 23-03-23 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | -22.73 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -17.83 | -22.75 | -20.4 | -31.42 | -38.57 | -42.55 | -57.14 | -57.95 | -50.35 | -41.77 | -40.66 | -41.01 | -43.05 | -41.28 | -41.83 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -17.77 | -22.73 | -20.02 | -30.46 | -35.21 | -38.93 | -53.25 | -54.03 | -46.75 | -38.57 | -39.45 | -40.14 | -43.62 | -48.2 | -48.78 |
| Net income 1 | -17.77 | -22.73 | -20.02 | -30.46 | -35.21 | -38.93 | -53.25 | -54.03 | -46.75 | -38.57 | -39.24 | -39.48 | -42.18 | -39.6 | -40.14 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4300 | -0.4500 | -0.3900 | -0.5900 | -0.6200 | -0.6800 | -0.9100 | -0.9200 | -0.7900 | -0.6200 | -0.5900 | -0.5800 | -0.6057 | -0.5800 | -0.5750 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-03-23 | 22-05-12 | 22-08-15 | 22-11-03 | 23-03-23 | 23-05-11 | 23-08-10 | 23-11-09 | 24-02-27 | 24-05-09 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 318 | 301 | 224 | 396 | 128 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -38.9 | -99 | -167 | -124 | -167 | -200 |
| ROE (net income / shareholders' equity) | - | - | -34.3% | -64.6% | -53.3% | -33.5% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 6.210 | 4.170 | 5.130 | 6.760 | - |
| Cash Flow per Share | - | - | -1.880 | - | - | - | - |
| Capex 1 | - | 0.26 | 0.28 | 0.51 | 0.5 | 1.83 | 3 |
| Capex / Sales | - | - | - | - | - | - | 4.5% |
| Announcement Date | 21-08-20 | 22-03-23 | 23-03-23 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
4.17
USD
Average target price
10.7
USD
Spread / Average Target
+156.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +72.87% | 294M | |
| +7.66% | 111B | |
| +11.24% | 106B | |
| -12.30% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.43% | 16.81B | |
| +38.76% | 12.54B | |
| -24.29% | 8.09B |
- Stock Market
- Equities
- VTYX Stock
- Financials Ventyx Biosciences, Inc.
